CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026GlobeNewsWire • Thursday
CytomX Therapeutics, Inc. (CTMX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/14/26
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)GlobeNewsWire • 08/27/26
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/07/26
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 08/06/26
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026GlobeNewsWire • 07/30/26
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of DirectorsGlobeNewsWire • 07/27/26
CytomX Therapeutics, Inc. (CTMX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/10/26
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of CancerGlobeNewsWire • 06/03/26
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory AffairsGlobeNewsWire • 05/18/26
CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue EstimatesZacks Investment Research • 05/08/26
CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 05/07/26
CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026GlobeNewsWire • 04/30/26
CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price LevelSeeking Alpha • 03/18/26
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 03/18/26